Cimzia

Phase 2Small molecule

UCB

Cimzia is one of 190 small molecule programs targeting Arthritis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

189

Competitors

Pipeline

Status by Indication[3][1]

Indication

ArthritisUnknown

Rheumatoid ArthritisUnknown

Crohn's DiseaseUnknown

Ulcerative ColitisActive, not recruiting

Psoriatic ArthritisUnknown

Ankylosing SpondylitisUnknown

ArthritisPreclinical

Unknown

Rheumatoid ArthritisPreclinical

Unknown

Crohn's DiseasePreclinical

Unknown

Ulcerative ColitisPhase 2

Active, not recruiting

Psoriatic ArthritisPreclinical

Unknown

Ankylosing SpondylitisPreclinical

Unknown

Competition

Competitive Landscape

791 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

Orencia

Bristol-Myers Squibb

Preclinical

47 2

Actemra

Cimzia

30 4

Cimzia

UCB

Phase 2

3 5

Simponi

Johnson & Johnson

Preclinical

19 6

Kevzara

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

14 7

Actos

Takeda

Preclinical

2 8

Celexa

AbbVie

Preclinical

1 9

Kineret

SSwedish Orphan Biovitrum

Preclinical

6 10

Rituxan

Pfizer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Rheumatoid Arthritis3 trials

Novel Imaging Markers for Rheumatoid Arthritis

Completed·UUniversity of California, San Francisco··NCT01773681·30 enrolled

Dose Reduction for Early Rheumatoid Arthritis Patients With Low Disease Activity

Unknown status·KKarolinska Institutet·Phase 4·NCT02466581·25 enrolled

Active Conventional Therapy Compared to Three Different Biologic Treatments in Early Rheumatoid Arthritis With Subsequent Dose Reduction

Unknown status·KKarolinska Institutet·Phase 4·NCT01491815·812 enrolled

Crohn's Disease2 trials

SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry

Completed· UCB logo

UCB··NCT00844285·3,072 enrolled

A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease

Completed· UCB logo

UCB·Phase 3·NCT00552344·403 enrolled

Ulcerative Colitis1 trial

Study of Cimzia for the Treatment of Ulcerative Colitis

Completed·UUniversity of Washington·Phase 2·NCT01090154·27 enrolled

Itching1 trial

Can TNF-Alpha Incomplete Secondary Responders Attain a Safe and Efficacious Response Switching to Cimzia

Completed·—·Phase 4·NCT01147341·37 enrolled

Recurrence1 trial

Cimzia Versus Mesalamine for Crohn's Recurrence

Terminated·MMilton S. Hershey Medical Center·Phase 4·NCT01696942·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Cimzia. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cimzia compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cimzia. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — UCB company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UCB

Cimzia

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Rheumatoid Arthritis3 trials

Crohn's Disease2 trials

Ulcerative Colitis1 trial

Itching1 trial

Recurrence1 trial

References

Drug Info

Quick Facts

Related News